Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-MRI exploration of cluster headache with [18F]F13640
2024-513873-36-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of befiradol (18F) in Cluster Headache (CH), sponsored by Hospices Civils de Lyon. Primary endpoint: Primary: Comparison of receptor density and perfusion between periods. Planned start Sep 2024; status: authorised.
02
Drugs
befiradol (18F)
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2024-513873-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513873-36-00.